Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Moderna's new mRNA flu vaccine shows 26.6% better protection than standard vaccines, notably in older adults.
Moderna's new mRNA flu vaccine, mRNA-1010, showed strong results in a Phase 3 trial, providing 26.6% more protection against the flu than a standard flu vaccine.
It was especially effective in adults 65 and older, with a 27.4% improvement.
The vaccine was effective across different age groups and health conditions.
Moderna plans to present the full trial data and publish the results in a peer-reviewed journal.
5 Articles
La nueva vacuna contra la gripe con ARNm de Moderna muestra un 26,6% de mejor protección que las vacunas estándar, especialmente en adultos mayores.